Tradestie Institutional Equity Comparison Engine · Market Close Aug 31, 2026

CRNX vs AKRO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRNX Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 3–3 Matrix Metrics)

CRNX Overall Winner 6-Pillar Tally: CRNX 3 – 1 AKRO (2 Tie) Matrix Metrics: CRNX 3 – 3 AKRO

As of Aug 31, 2026, Crinetics Pharmaceuticals, Inc. (CRNX) is the stronger overall head-to-head candidate over Akero Therapeutics, Inc. (AKRO) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). CRNX carries a Unified Composite Score of 46.8/100 (HOLD) at $84.95 (N/M Forward P/E, -527.4% operating margin), whereas AKRO carries 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While AKRO currently prints a higher short-term Unified Composite Score (60.0/100 BUY vs. CRNX 46.8/100 HOLD), CRNX captures the overall institutional head-to-head verdict (3–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-527.4% vs. 0.0% operating margin) and revenue trajectory (+2336.3% vs. +0.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRNX vs AKRO
CRNX NASDAQ Head-to-Head Winner
Crinetics Pharmaceuticals, Inc.
Pharmaceutical Preparations
$84.95
+0.13% 1D
Market Cap $9.0B
TTM Revenue $42M
Forward P/E N/M
Beta / 30D Vol 0.29β · 2% Vol
Unified Composite Score
46.8 / 100 HOLD
Tech 45.0 Fund 48.0 Flow 60.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (36.0% over 20 days), RSI 90
RSI-14: 89.6 · SMA20: $84.53 · SMA50: $74.83
AKRO NASDAQ
Akero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$54.65
+0.32% 1D
Market Cap $4.5B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.90β · 2% Vol
Unified Composite Score
60.0 / 100 BUY
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 67
RSI-14: 67.3 · SMA20: $54.36 · SMA50: $52.91

6-Pillar Scorecard Institutional Category Breakdown (CRNX 3 – 1 AKRO)

Columns: Metric · CRNX · AKRO
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale CRNX
Revenue Growth (YoY) +2336.3% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $42M N/A
Market Cap $9.0B $4.5B
3. Profitability & Quality AKRO
Gross Margin N/A N/A
Operating Margin -527.4% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -42.4% -34.5%
4. Balance Sheet & Cash Flow CRNX
Cash Generation (TTM) -$425M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $8.3M Net Cash $11.95 Book/Sh · -34.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CRNX
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 0.5% (<1st %ile) 7.3% (30th %ile)
Put/Call OI Skew 0.07x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Pharmaceutical Preparations Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRNX (3) vs AKRO (3)
Institutional Metric CRNX AKRO Criterion Row Edge
Market Capitalization
Scale
$9.0B $4.5B Larger Scale CRNX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+2336.3% +0.0% Higher Growth CRNX
Operating Margin (TTM)
Profitability
-527.4% 0.0% Higher Margin AKRO
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-42.4% -34.5% Higher ROE AKRO
52-Week Range Position
Momentum
100% ($30–$85) 90% ($21–$58) Stronger Trend CRNX
Beta / 30D Volatility
Risk Regime
0.29β · 2% Vol 0.90β · 2% Vol Lower Realized Risk Tie
Unified Institutional Score
Composite Signal
46.8 / 100 (HOLD) 60.0 / 100 (BUY) Higher Composite AKRO
Trailing 12M Revenue (USD)
Operating Scale
$42M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$425M ($8.3M Net Cash) N/A ($11.95 Book/Sh · -34.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CRNX +7.62 pp
CRNX: +8.99% · AKRO: +1.37%
3M Horizon CRNX +7.38 pp
CRNX: +29.86% · AKRO: +22.48%
6M Horizon CRNX +38.22 pp
CRNX: +54.65% · AKRO: +16.43%
1Y Horizon CRNX +38.22 pp
CRNX: +54.65% · AKRO: +16.43%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRNX vs AKRO. Trailing 12-month operating profitability (CRNX -527.4% vs AKRO 0.0%) and valuation multiples (CRNX N/M vs AKRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CRNX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$42M
Gross MarginN/A
Op. Margin-527.4%
ROE / Fwd P/E-42.4% · N/M
AKRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-34.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRNX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.5%
IV Percentile <1st %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact CRNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AKRO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 7.3%
IV Percentile 30th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AKRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.0B market capitalization and -527.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AKRO Moat Profile Cyclical / Execution-Driven Positioning
Pharmaceutical Preparations Operator
Competes within the Pharmaceutical Preparations value chain with $4.5B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CRNX vs AKRO Key Questions & Quantitative Answers

As of Aug 31, 2026, Crinetics Pharmaceuticals, Inc. (CRNX) is the stronger overall head-to-head candidate over Akero Therapeutics, Inc. (AKRO) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). CRNX carries a Unified Composite Score of 46.8/100 (HOLD) at $84.95 (N/M Forward P/E, -527.4% operating margin), whereas AKRO carries 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While AKRO currently prints a higher short-term Unified Composite Score (60.0/100 BUY vs. CRNX 46.8/100 HOLD), CRNX captures the overall institutional head-to-head verdict (3–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-527.4% vs. 0.0% operating margin) and revenue trajectory (+2336.3% vs. +0.0% YoY).

CRNX leads the Growth & Scale pillar: CRNX posts +2336.3% YoY revenue growth and +0.0% YoY earnings growth on $42M TTM revenue (N/A gross margin, -527.4% operating margin), compared with AKRO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CRNX generates $42M in USD-normalized revenue versus N/A for AKRO. In operating R&D and SG&A reinvestment, CRNX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AKRO.

CRNX and AKRO trade at balanced relative valuation multiples. CRNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas AKRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRNX (-42.4% ROE) versus AKRO (-34.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CRNX carries 0.5% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.29β · 2% Vol realized risk). By comparison, AKRO carries 7.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Aug 31, 2026. For educational research only; not investment advice.